Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | PDE6D | O43924 | 1/20 | 0.30 |
| ▸ | PDE5A | O76074 | 1/20 | 0.30 |
| ▸ | PDE6A | P16499 | 1/20 | 0.30 |
| ▸ | PDE6G | P18545 | 1/20 | 0.30 |
| ▸ | PDE6B | P35913 | 1/20 | 0.30 |
| ▸ | PDE6C | P51160 | 1/20 | 0.30 |
| ▸ | PDE6H | Q13956 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24004736 | 0.79 | PTGER4 (0.39) | PTGER4KDM4EALDH1A1HPGD | |
| SCHEMBL27695518 | 0.72 | PTGER4 (0.46) | PTGER4 | |
| SCHEMBL21741607 | 0.70 | PTGER4 (0.57) | PTGER4ALDH1A1 | |
| SCHEMBL23109113 | 0.70 | PTGER4 (0.38) | PTGER4KDM4E | |
| SCHEMBL3946713 | 0.70 | PTGER4 (0.52) | PTGER4 | |
| SCHEMBL23876557 | 0.70 | PTGER4 (0.35) | PTGER4LMNAHTTKDM4EALDH1A1 | |
| SCHEMBL30595006 | 0.69 | PTGER4 (0.48) | PTGER4KDM4EALDH1A1 | |
| SCHEMBL1626358 | 0.68 | PTGER4 (0.55) | PTGER4 | |
| SCHEMBL1624736 | 0.68 | PTGER4 (0.57) | PTGER4 | |
| SCHEMBL25005092 | 0.68 | PTGER4 (0.37) | PTGER4LMNAKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11254675-B2 | Process for preparation of grapiprant | CADILA HEALTHCARE LIMITED (IN) | 2022-02-22 | — | — | US | disclosed |
| US-20210347776-A1 | PROCESS FOR PREPARATION OF GRAPIPRANT | CADILA HEALTHCARE LIMITED (IN) | 2021-11-11 | — | — | US | disclosed |
| US-20210079000-A1 | PROCESS FOR PREPARATION OF GRAPIPRANT | CADILA HEALTHCARE LIMITED (IN) | 2021-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210347776-A1 | PROCESS FOR PREPARATION OF GRAPIPRANT | ADCYAP1R1, GANC, DRD4 | PTGER4 271/4885TSHR 3014/4885LMNA 677/4885 |
| US-11254675-B2 | Process for preparation of grapiprant | ADCYAP1R1, GANC, DRD4 | PTGER4 271/4885TSHR 3014/4885LMNA 677/4885 |
| US-20210079000-A1 | PROCESS FOR PREPARATION OF GRAPIPRANT | ADCYAP1R1, GANC, DRD4 | PTGER4 271/4885TSHR 3014/4885LMNA 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.